- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.06. | ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons | ||
| 03.06. | SpyGlass Pharma secures $75m for ophthalmic drug delivery platform | ||
| 03.06. | ASCO25: Kura's Phase II ziftomenib results trigger NDA acceptance from FDA | ||
| 03.06. | ASCO25: Genmab's Rina-S en route to 'blockbuster potential' amid further positive data | ||
| 03.06. | FDA grants expanded access to ImmunityBio's Anktiva for lymphopenia | ||
| 03.06. | Regeneron to acquire rights for Hansoh's HS-20094 therapy | ||
| 02.06. | BMS outlays $11bn to join BioNTech's development of bispecific cancer drug | ||
| 02.06. | Sanofi to expand immunology offerings with Blueprint Medicines | ||
| 02.06. | ASCO25: J&J's Carvykti shows strong efficacy across multiple myeloma risk groups | ||
| 02.06. | Sanofi and Regeneron report results from two Phase III trials of COPD treatment | ||
| 02.06. | ASCO25: MSD's KRAS G12C drug shows early promise in Phase I | ||
| 02.06. | ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles | ||
| 02.06. | CirCode Biomed gains clearance from FDA for RNA drug HM2002 | ||
| 02.06. | Zymeworks' zanidatamab gains approval in China for biliary tract cancer | ||
| 30.05. | ASCO25: Pfizer's Braftovi combo boasts 47% drop in disease progression in mCRC | ||
| 30.05. | EyePoint advances with Duravyu Phase III trial | ||
| 30.05. | Alvotech and Advanz to commercialise biosimilars in Europe | ||
| 30.05. | FDA rejects Stealth Bio's Barth syndrome treatment after 16.5-month review | ||
| 30.05. | Astellas and Evopoint sign ADC licensing deal | ||
| 30.05. | Daiichi Sankyo and MSD withdraw US application for lung cancer BLA | ||
| 29.05. | Solid tumours: CAR-T therapies' Waterloo | ||
| 29.05. | Regeneron to deploy Telesis Bio's Gibson SOLA at R&D facilities | ||
| 29.05. | iTeos to shut down following $2bn GSK-partnered TIGIT asset failure | ||
| 29.05. | FDA approves Eton's application for hydrocortisone oral solution | ||
| 29.05. | EC approves BMS' nivolumab SC formulation for solid tumours |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .